Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.02
(-12.0%)
HKD 0.02
(-12.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.72 Billion HKD | -18.54% |
| 2022 | 2.12 Billion HKD | -17.13% |
| 2021 | 2.55 Billion HKD | 0.65% |
| 2020 | 2.54 Billion HKD | -36.45% |
| 2019 | 4 Billion HKD | 19.68% |
| 2018 | 3.34 Billion HKD | -2.95% |
| 2017 | 3.44 Billion HKD | 9.19% |
| 2016 | 3.15 Billion HKD | 19.93% |
| 2015 | 2.62 Billion HKD | 8.37% |
| 2014 | 2.42 Billion HKD | 49.25% |
| 2013 | 1.62 Billion HKD | 0.88% |
| 2012 | 1.61 Billion HKD | 1.52% |
| 2011 | 1.58 Billion HKD | 11.3% |
| 2010 | 1.42 Billion HKD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.69 Billion HKD | 0.0% |
| 2023 Q1 | 1.82 Billion HKD | -13.82% |
| 2023 Q3 | 1.72 Billion HKD | -5.47% |
| 2023 Q2 | 1.82 Billion HKD | 0.0% |
| 2023 Q4 | 1.72 Billion HKD | 0.0% |
| 2023 FY | 1.72 Billion HKD | -18.54% |
| 2022 Q2 | 2.45 Billion HKD | 0.0% |
| 2022 FY | 2.12 Billion HKD | -17.13% |
| 2022 Q4 | 2.12 Billion HKD | 0.0% |
| 2022 Q3 | 2.12 Billion HKD | -13.77% |
| 2022 Q1 | 2.45 Billion HKD | -3.9% |
| 2021 Q2 | 2.45 Billion HKD | 0.0% |
| 2021 Q1 | 2.45 Billion HKD | -3.47% |
| 2021 Q4 | 2.55 Billion HKD | 0.0% |
| 2021 FY | 2.55 Billion HKD | 0.65% |
| 2021 Q3 | 2.55 Billion HKD | 4.26% |
| 2020 Q2 | 4.23 Billion HKD | 0.0% |
| 2020 FY | 2.54 Billion HKD | -36.45% |
| 2020 Q3 | 2.54 Billion HKD | -40.02% |
| 2020 Q4 | 2.54 Billion HKD | 0.0% |
| 2020 Q1 | 4.23 Billion HKD | 5.96% |
| 2019 Q3 | 4 Billion HKD | 2.97% |
| 2019 Q2 | 3.88 Billion HKD | 0.0% |
| 2019 Q1 | 3.88 Billion HKD | 16.22% |
| 2019 Q4 | 4 Billion HKD | 0.0% |
| 2019 FY | 4 Billion HKD | 19.68% |
| 2018 Q4 | 3.34 Billion HKD | 0.0% |
| 2018 Q2 | 3.57 Billion HKD | 0.0% |
| 2018 FY | 3.34 Billion HKD | -2.95% |
| 2018 Q1 | 3.57 Billion HKD | 3.71% |
| 2018 Q3 | 3.34 Billion HKD | -6.43% |
| 2017 Q1 | 3.56 Billion HKD | 12.89% |
| 2017 Q4 | 3.44 Billion HKD | 0.0% |
| 2017 Q3 | 3.44 Billion HKD | -3.28% |
| 2017 FY | 3.44 Billion HKD | 9.19% |
| 2017 Q2 | 3.56 Billion HKD | 0.0% |
| 2016 Q2 | 2.67 Billion HKD | 0.0% |
| 2016 FY | 3.15 Billion HKD | 19.93% |
| 2016 Q3 | 3.15 Billion HKD | 17.94% |
| 2016 Q1 | 2.67 Billion HKD | 1.69% |
| 2016 Q4 | 3.15 Billion HKD | 0.0% |
| 2015 Q1 | 3.03 Billion HKD | 25.13% |
| 2015 Q4 | 2.62 Billion HKD | 0.0% |
| 2015 Q3 | 2.62 Billion HKD | -13.39% |
| 2015 Q2 | 3.03 Billion HKD | 0.0% |
| 2015 FY | 2.62 Billion HKD | 8.37% |
| 2014 Q4 | 2.42 Billion HKD | 0.0% |
| 2014 Q3 | 2.42 Billion HKD | 37.17% |
| 2014 Q1 | 1.76 Billion HKD | 8.81% |
| 2014 FY | 2.42 Billion HKD | 49.25% |
| 2014 Q2 | 1.76 Billion HKD | 0.0% |
| 2013 Q2 | 1.58 Billion HKD | 0.0% |
| 2013 Q4 | 1.62 Billion HKD | 0.0% |
| 2013 Q3 | 1.62 Billion HKD | 2.87% |
| 2013 FY | 1.62 Billion HKD | 0.88% |
| 2013 Q1 | 1.58 Billion HKD | -1.94% |
| 2012 Q3 | 1.61 Billion HKD | -3.43% |
| 2012 Q2 | 1.66 Billion HKD | 0.0% |
| 2012 Q4 | 1.61 Billion HKD | 0.0% |
| 2012 FY | 1.61 Billion HKD | 1.52% |
| 2011 Q4 | 1.58 Billion HKD | 0.0% |
| 2011 FY | 1.58 Billion HKD | 11.3% |
| 2010 FY | 1.42 Billion HKD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 907.46 Million HKD | -90.347% |
| Grand Pharmaceutical Group Limited | 22.51 Billion HKD | 92.328% |
| Extrawell Pharmaceutical Holdings Limited | 1.28 Billion HKD | -34.194% |
| Wai Yuen Tong Medicine Holdings Limited | 2.09 Billion HKD | 17.554% |
| Qianhai Health Holdings Limited | 478.11 Million HKD | -261.279% |
| Lee's Pharmaceutical Holdings Limited | 2.89 Billion HKD | 40.244% |
| Essex Bio-Technology Limited | 2.82 Billion HKD | 38.911% |
| PuraPharm Corporation Limited | 843.96 Million HKD | -104.67% |
| SSY Group Limited | 11.96 Billion HKD | 85.565% |
| JBM (Healthcare) Limited | 1.38 Billion HKD | -24.385% |
| Jacobson Pharma Corporation Limited | 3.48 Billion HKD | 50.462% |
| China Resources Pharmaceutical Group Limited | 271.69 Billion HKD | 99.364% |